Réf.
2023/CDDDE/9555
Type d'offre
Poste terrain
Type de contrat
Contrat de prestation de services
Domaines d'expertises
Politique de la santé ; Systèmes de santé ; Suivi et évaluation
Sous-thématique
Cancer ; Financement des systèmes de santé ; Gouvernance des systèmes de santé
Date limite de candidature
24/07/2023 16:53
Durée de la mission
Court terme
Contrat
Indépendant / Entrepreneur Individuel
Durée
From August to November 2023
Data Collection and Verification - Economic evaluation (H/F)
Département Santé - DEPSAN > Pôle Initiative 5% et Pandémies
Mis en ligne le : 17/07/2023
ASIE
PHILIPPINES
MANILA
Description de la mission
The SUCCESS project is hiring a data collection consultant to work with other members of the team and collect data that are required for the costing study. The consultant will be responsible for the following:
- Train with the study team on use of tools and data collection templates
- Collaborate with the Department of Health - Cancer Control Division on the use of the C4P tool
- Provide input on tools and data collection templates
- Gather primary and secondary data from Department of Health programme managers and other stakeholders
- Report to study team weekly about progress with data collection
- Attend weekly team meetings
- Support requests from study team
Confidentiality of information and intellectual property
- The contracted company and its personnel undertake to carry out the assigned tasks in accordance with the highest standards of ethical competence and professional integrity. All data collected and databases are confidential, and therefore may not be shared or used in other media by the consulting team.
- The ownership, title and industrial and intellectual property rights of the results of the consultancy, as well as of the reports and other documents produced, are the property of the SUCCESS Project.
- At the beginning of the process, the team must sign a confidentiality and intellectual property agreement.
Description du projet ou contexte
Cervical cancer is one of the most common preventable forms of cancer, but it is the fourth most common cancer among women globally and the leading cause of death among HIV-infected women.[1],[2],[3] An estimated 604,127 new cases of cervical cancer were diagnosed worldwide and 341,831 women died from the disease in 2020. An overwhelming majority (90%) of these cervical cancer deaths occur in low- and middle-income countries (LMICs), which often have poor health infrastructure.[4] Nearly all cases of cervical cancer (99%) are related to infection with high-risk human papillomavirus (HPV), an extremely common virus transmitted through sexual contact.[5],[6]
To address this situation, the World Health Organization (WHO) has launched a strategy to accelerate the elimination of cervical cancer worldwide. This strategy aims to ensure that, by 2030, 90% of girls are vaccinated against HPV, 90% of adult women have access to screening services with a highly effective test, and 70% of women with cancer or precancerous lesions receive the treatment they need.
WHO estimates that a total of USD 10.5 billion is required to finance cervical cancer eradication in low- and low-to-middle-income countries by 2030, where a large portion of this amount (equivalent to USD 1.8 per capita) should be frontloaded to rapidly establish and scale up services; 6.2 USD of this figure is needed for vaccination programs; 2.1 USD for facility utilization; 1.3 USD for consumables, 0.5 USD for human resources and 0.4 USD for equipment; by 2019 TogetHER for Health, reported that only one-seventh of this amount was invested in these countries[7].
In this context, the SUCCESS (Scale up cervical cancer elimination with secondary prevention strategy) project is supporting four countries (Guatemala, Burkina Faso, Côte d'Ivoire and the Philippines) to expand their screening programs with an emphasis on HPV DNA testing and ablative treatment of precancerous cervical lesions as part of their interventions, the project plans to estimate the costs of implementing cervical cancer prevention interventions over a 5-year period in each of the implementing countries and involves an exercise to estimate the costs of integrating secondary prevention (screening) and tertiary prevention (early treatment of precancerous lesions) into the continuum of care through services integrated into health facilities; this also includes a comparative analysis of costs in different potential scenarios.
This exercise will be conducted using an adapted version of the Costing Tool for Cervical Cancer Prevention and Control (C4P), developed for WHO. This tool is intended for use by LMIC program managers to plan cervical cancer control strategies and make multi-year cost projections. It uses a bottom-up, input-based approach (i.e., unit cost X quantity of good or service). The C4P-SUCCESS tool will reflect the country's screening and treatment algorithm.
These costs will include two broad categories:
- Provision of services (e.g., personnel salaries, equipment, supplies, laboratory fees), and
- Program support activities (e.g., training, IEC development and deployment, supervision, M&E).
[1]World Health Organization. Global strategy for accelerating the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020-2030. Vol 2.; 2020.
[2] World Health Organization. Analysis and use of data from health facilities: guidance for HIV program managers.; 2018. https://www.who.int/healthinfo/FacilityAnalysisGuide_HIV.pdf
[3] Kelly HA, Sawadogo B, Chikandiwa A, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of antiretroviral therapy. AIDS. 2017;31(2):273-285.
[4] UICC. GLOBOCAN 2020: New Global Cancer Data.; 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
[5] UICC. GLOBOCAN 2020: New Global Cancer Data; 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
[6]Castle PE, Glass AG, Rush BB, et al. Clinical detection of human papillomavirus predicts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30(25):3044-3050. doi:10.1200/JCO.2011.38.8389.
[7] WHO and Together for Health, 2020 (The Economist Intelligence Unit Limited 2021. UICC, Expertise France, Unitaid).
Profil souhaité
Required Qualifications:
- Bachelor’s degree in economics, majoring in Health Economics or other similar degree
- Experience working with the Department of Health in the Philippines
- Experience working with national and local government stakeholders and international organizations
- Experienced in data collection and development of costing tools
- Excellent written and communication skills
- Proficiency in MS Office Applications (Word, PowerPoint, and Excel)
- Experience working in programmes or projects related to cervical cancer prevention or reproductive health, desirable
- Working knowledge of cost analysis
- Residency in the Philippines preferred
Professional Skills:
- Good organizational, communications and people management skills
- Good verbal skills
- Proficiency in English
- Strong analytical, problem-solving, and decision-making skills
- Sound business ethics, including the protection of proprietary and confidential information
- Proven experience working with multi-disciplinary teams
Informations complémentaires
Anticipated period of performance:
- From August to November 2023
Liaising with:
- The consultant will liaise with a designated Jhpiego country office staff member in the Philippines to ensure that the consultants’ activities are aligned with Jhpiego activities and operations.
Employed by:
- Expertise France will contract the consultant.
- If the candidate is not currently based in the Philippines, relocation costs will not be covered by the contract.
- References will be requested if candidates proceed to interview
Reporting to:
- The consultant will report directly to the Health Economist at Levin & Morgan, LLC
We invite qualified candidates to please submit a CV and a cover letter in English.
